NOVACYT Novacyt S.A.
("Novacyt", the "Company" or the "Group")
DHSC application for summary judgment dismissed
Paris, France, and Eastleigh and Manchester, UK - 1 May 2024 - Following the announcement on19 April 2024, Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, notes the judgment by Mrs Justice Jefford following the Pre-TrialReview heard on 30 April 2024. Mrs Justice Jefford has dismissed the application by the Department of Health and Social Care ("DHSC") for summary judgment.
The Pre-Trial Review has now concluded, and the trial hearing has been listed to commence on 10 June 2024, and finish on 4 July 2024. The Company expects the court to reserve judgment, meaning that the outcome of the trial will not be known on 4 July 2024.
Contacts | ||
Novacyt SA | https://novacyt.com/investors | |
Lyn Rees, Chief Executive Officer | Via Walbrook PR | |
Steve Gibson, Chief Financial Officer | ||
SP Angel Corporate Finance LLP (Nominated Adviser and Broker) | +44 (0)20 3470 0470 | |
Matthew Johnson / Charlie Bouverat (Corporate Finance) | ||
Vadim Alexandre / Rob Rees (Corporate Broking) | ||
Deutsche Numis (Joint Broker) | +44 (0)20 7260 1000 | |
Freddie Barnfield / Duncan Monteith / Michael Palser | ||
Allegra Finance (French Listing Sponsor) | +33 (1) 42 22 10 10 | |
Rémi Durgetto / Yannick Petit | r.durgetto@allegrafinance.com/ y.petit@allegrafinance.com | |
Walbrook PR (Financial PR & IR) | +44 (0)20 7933 8780 or novacyt@walbrookpr.com | |
Stephanie Cuthbert / Paul McManus / | +44 (0)7796 794 663 / +44 (0)7980 541 893 | |
Phillip Marriage / Alice Woodings | +44 (0)7867 984 082 / +44 (0)7407 804 654 |
About Novacyt Group (www.novacyt.com)
Novacyt is an international molecular diagnostics company providing a broad portfolio of integrated technologies and services, primarily focused on the delivery of genomic medicine. The Company develops, manufactures, and commercialises a range of molecular assays and instrumentation to deliver workflows and services that enable seamless end-to-end solutions from sample to result across multiple sectors including human health, animal health and environmental.
The Company is divided into three business segments:
Clinical | Broad portfolio of human clinical in vitro diagnostic products, workflows and services | |
focused on three therapeutic areas: | ||
• Reproductive Health: NIPT, Cystic Fibrosis and other rapid aneuploidy tests | ||
• | Precision Medicine: DPYD genotyping assay | |
• | Infectious Diseases: Winterplex, multiplex winter respiratory PCR panel |
Instrumentation Portfolio of next generation size selection DNA sample preparation platforms and rapid PCR machines, including:
-
Ranger® Technology: automated DNA sample preparation and target enrichment technology
MyGo: real-time quantitative PCR (qPCR) instruments
Research Use Only Range of services for the research industry:
- Design, manufacture, and supply of high-performance qPCR assays and workflows for use in human health, agriculture, veterinary and environmental, to support global health organisations and the research industry
- Pharmaceutical research services: whole genome sequencing (WGS) / whole exome sequencing (WES)
Novacyt is headquartered in Vélizy in France with offices in the UK (in Stokesley, Eastleigh and Manchester), Taipei, Singapore, the US and Canada and has a commercial presence in over 65 countries. The Company is listed on the London Stock Exchange's AIM market ("NCYT") and on the Paris Stock Exchange Euronext Growth ("ALNOV").
For more information, please refer to the website: www.novacyt.com
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Novacyt SA published this content on 01 May 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 01 May 2024 11:14:02 UTC.
